TITLE

Weight-Loss Pharmacotherapy: A Brief Review

AUTHOR(S)
Huizinga, Mary Margaret
PUB. DATE
September 2007
SOURCE
Clinical Diabetes;Fall2007, Vol. 25 Issue 4, p135
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reviews current pharmacological options for weight loss and provides a brief synopsis of potential future options. It says that the medical treatment of obesity is aimed at decreasing appetite, alterating absorption of calories and increasing thermogenesis. It states that the two agents available for the long-term treatment of obesity include sibutramine which acts as an anorectic agent and orlistat which blocks the absorption of fat by inhibiting the enzyme lipase.
ACCESSION #
27421330

 

Related Articles

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p14 

    The article examines some weight loss drugs in the United States. Xenical or Orlistat are drugs that hinder fat absorption into the gastrointestinal tract. An appetite suppressant, Meridia prevents the reabsorption of serotonin, a hormone in the brain that is released when a patient is full from...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • Sibutramine is best for weight loss.  // Pulse;1/30/2008, Vol. 68 Issue 3, p11 

    The article reports on the result of the meta-analysis of data from head-to-head trials of obesity medication in Great Britain. It suggests that patients lose more weight with sibutramine than orlistat. It states that researchers found sibutramine was significantly more efficacious, with a...

  • Anti Obesity Drugs. Huppertz, Christine // Encyclopedic Reference of Molecular Pharmacology;2004, p97 

    The article presents an encyclopedia entry for the term "anti-obesity drugs," which are drugs that help to control appetite and reduce weight. It discusses the mechanism of action of anti-obesity drugs. It also provides information on the clinical use and side effects of these drugs. Several...

  • Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. Cheskin, Lawrence J. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49 

    Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.

  • Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J. // Drug Safety;2006, Vol. 29 Issue 4, p277 

    Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was...

  • DRUGS FOR OBESITY. Mead, Mike // Practice Nurse;9/10/2004, Vol. 28 Issue 4, p64 

    Focuses on prescription drugs available to help obese patients to lose weight. Clinical indications of Sibutramine and Orlistat; Contraindications and side effects of the drugs; Importance of monitoring patients who are taking drug therapy.

  • New drug policy in childhood obesity. Molnár, D.; Molnár, D // International Journal of Obesity;Sep2005 Supplement 2, Vol. 29, pS62 

    Objective: To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.Methods: The paper reviews current and investigational antiobesity drugs.Results: At present, there are only...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics